BACKGROUND: Fatigue is a highly prevalent and clinically significant symptom of advanced prostate cancer. To date, however, there are no published controlled trials of interventions for fatigue in men with prostate cancer. METHODS: This 6-week, randomized, double-blind, placebo-controlled design evaluated the efficacy of methylphenidate to treat fatigue in prostate cancer patients. Inclusion criteria included men with advanced prostate cancer and the presence of moderate to severe fatigue. Patients with major depression, hypothyroidism, uncontrolled hypertension, arrhythmia, or anemia were excluded. Fatigue levels, blood pressure, pulse, and other safety concerns were monitored regularly. RESULTS:Thirty-two subjects were randomized to methylphenidate (n=16) or placebo (n=16). Brief Fatigue Inventory total scores significantly decreased for both groups; however, the methylphenidate group, as compared with placebo, reported greater decrease on Brief Fatigue Inventory severity scores (P=.03) and a trend toward greater decrease on Brief Fatigue Inventory total scores (P=.07). A significantly greater number of subjects in the methylphenidate group versus the placebo group demonstrated clinically significant improvement in fatigue on total Brief Fatigue Inventory scores (7 of 10 vs 3 of 13) and Brief Fatigue Inventory severity scores (8 of 10 vs 3 of 13). Importantly, 6 subjects in the methylphenidate group discontinued because of increased blood pressure or tachycardia. There were no serious adverse events. CONCLUSIONS:Methylphenidate is effective in treating fatigue in men with prostate cancer; however, oncologists need to monitor for possible pulse and blood pressure elevations.
RCT Entities:
BACKGROUND:Fatigue is a highly prevalent and clinically significant symptom of advanced prostate cancer. To date, however, there are no published controlled trials of interventions for fatigue in men with prostate cancer. METHODS: This 6-week, randomized, double-blind, placebo-controlled design evaluated the efficacy of methylphenidate to treat fatigue in prostate cancerpatients. Inclusion criteria included men with advanced prostate cancer and the presence of moderate to severe fatigue. Patients with major depression, hypothyroidism, uncontrolled hypertension, arrhythmia, or anemia were excluded. Fatigue levels, blood pressure, pulse, and other safety concerns were monitored regularly. RESULTS: Thirty-two subjects were randomized to methylphenidate (n=16) or placebo (n=16). Brief Fatigue Inventory total scores significantly decreased for both groups; however, the methylphenidate group, as compared with placebo, reported greater decrease on Brief Fatigue Inventory severity scores (P=.03) and a trend toward greater decrease on Brief Fatigue Inventory total scores (P=.07). A significantly greater number of subjects in the methylphenidate group versus the placebo group demonstrated clinically significant improvement in fatigue on total Brief Fatigue Inventory scores (7 of 10 vs 3 of 13) and Brief Fatigue Inventory severity scores (8 of 10 vs 3 of 13). Importantly, 6 subjects in the methylphenidate group discontinued because of increased blood pressure or tachycardia. There were no serious adverse events. CONCLUSIONS:Methylphenidate is effective in treating fatigue in men with prostate cancer; however, oncologists need to monitor for possible pulse and blood pressure elevations.
Authors: V Mock; A Atkinson; A Barsevick; D Cella; B Cimprich; C Cleeland; J Donnelly; M A Eisenberger; C Escalante; P Hinds; P B Jacobsen; P Kaldor; S J Knight; A Peterman; B F Piper; H Rugo; P Sabbatini; C Stahl Journal: Oncology (Williston Park) Date: 2000-11 Impact factor: 2.990
Authors: R K Portenoy; H T Thaler; A B Kornblith; J M Lepore; H Friedlander-Klar; E Kiyasu; K Sobel; N Coyle; N Kemeny; L Norton Journal: Eur J Cancer Date: 1994 Impact factor: 9.162
Authors: Carmen P Escalante; Christina Meyers; James M Reuben; Xuemei Wang; Wei Qiao; Ellen Manzullo; Ricardo H Alvarez; Phuong Khanh Morrow; Ana M Gonzalez-Angulo; Xin Shelley Wang; Tito Mendoza; Wenli Liu; Holly Holmes; Jessica Hwang; Katherine Pisters; Michael Overman; Charles Cleeland Journal: Cancer J Date: 2014 Jan-Feb Impact factor: 3.360
Authors: Pedro Nazareth Aguiar Junior; Carmelia Maria Noia Barreto; Daniel de Iracema Gomes Cubero; Auro Del Giglio Journal: Support Care Cancer Date: 2019-07-13 Impact factor: 3.603
Authors: Sarah A Morrow; Audrey Smerbeck; Kara Patrick; Diane Cookfair; Bianca Weinstock-Guttman; Ralph H B Benedict Journal: J Neurol Date: 2012-09-23 Impact factor: 4.849
Authors: Christina K Ullrich; Veronica Dussel; Liliana Orellana; Tammy I Kang; Abby R Rosenberg; Chris Feudtner; Joanne Wolfe Journal: Cancer Date: 2018-10-06 Impact factor: 6.860